Health, Subjective
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CelltrionKorea - Incheon
3 programs3
CT-P13 SC Auto-injectorPhase 11 trial
CTL0801Phase 11 trial
Drug: Treatment APhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
CelltrionCTL0801
CelltrionDrug: Treatment A
CelltrionCT-P13 SC Auto-injector
Clinical Trials (3)
Total enrollment: 296 patients across 3 trials
A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers
Start: Jul 2021Est. completion: Sep 202137 patients
Phase 1Completed
A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers
Start: Jul 2021Est. completion: Oct 202141 patients
Phase 1Completed
CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects
Start: Feb 2018Est. completion: Jul 2018218 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space